101 related articles for article (PubMed ID: 20198346)
1. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
Zhou X; Yang XY; Popescu NC
Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells.
Zhou W; Feng X; Han Han ; Guo S; Wang G
Sci Rep; 2016 Jun; 6():28004. PubMed ID: 27292433
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells.
Zhou Q; Shaw PG; Davidson NE
Breast Cancer Res Treat; 2009 Sep; 117(2):443-51. PubMed ID: 18683042
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.
Jonsson M; Ragnum HB; Julin CH; Yeramian A; Clancy T; Frikstad KM; Seierstad T; Stokke T; Matias-Guiu X; Ree AH; Flatmark K; Lyng H
Br J Cancer; 2016 Oct; 115(8):929-939. PubMed ID: 27599042
[TBL] [Abstract][Full Text] [Related]
5. Selenium-containing histone deacetylase inhibitors for melanoma management.
Gowda R; Madhunapantula SV; Desai D; Amin S; Robertson GP
Cancer Biol Ther; 2012 Jul; 13(9):756-65. PubMed ID: 22669577
[TBL] [Abstract][Full Text] [Related]
6. A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors.
Low JS; Tao Q; Ng KM; Goh HK; Shu XS; Woo WL; Ambinder RF; Srivastava G; Shamay M; Chan AT; Popescu NC; Hsieh WS
Oncogene; 2011 Apr; 30(16):1923-35. PubMed ID: 21217778
[TBL] [Abstract][Full Text] [Related]
7. In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC).
Tambunan US; Bramantya N; Parikesit AA
BMC Bioinformatics; 2011; 12 Suppl 13(Suppl 13):S23. PubMed ID: 22373132
[TBL] [Abstract][Full Text] [Related]
8. The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo.
Susanto JM; Colvin EK; Pinese M; Chang DK; Pajic M; Mawson A; Caldon CE; Musgrove EA; Henshall SM; Sutherland RL; Biankin AV; Scarlett CJ
Int J Oncol; 2015 May; 46(5):2223-30. PubMed ID: 25695794
[TBL] [Abstract][Full Text] [Related]
9. Metabolomic, DNA Methylomic, and Transcriptomic Profiling of Suberoylanilide Hydroxamic Acid Effects on LPS-Exposed Lung Epithelial Cells.
Chou PJ; Sarwar MS; Wang L; Wu R; Li S; Hudlikar RR; Wang Y; Su X; Kong AN
Cancer Prev Res (Phila); 2023 Jun; 16(6):321-332. PubMed ID: 36867722
[TBL] [Abstract][Full Text] [Related]
10. Improving therapeutic potential in breast cancer via histone deacetylase inhibitor loaded nanofibrils.
Senthilkumar P; Gogoi B; Dhan SS; Subramani R; Pushparaj C; Mahesh A
Drug Dev Res; 2024 Apr; 85(2):e22172. PubMed ID: 38488434
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor.
Xu W; Ngo L; Perez G; Dokmanovic M; Marks PA
Proc Natl Acad Sci U S A; 2006 Oct; 103(42):15540-5. PubMed ID: 17030815
[TBL] [Abstract][Full Text] [Related]
12. Suberoylanilide hydroxamic acid upregulates reticulophagy receptor expression and promotes cell death in hepatocellular carcinoma cells.
Li JY; Tian T; Han B; Yang T; Guo YX; Wu JY; Chen YS; Yang Q; Xie RJ
World J Gastroenterol; 2023 Sep; 29(34):5038-5053. PubMed ID: 37753370
[TBL] [Abstract][Full Text] [Related]
13. Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells.
Park S; Park JA; Kim YE; Song S; Kwon HJ; Lee Y
Cell Stress Chaperones; 2015 Jan; 20(1):149-57. PubMed ID: 25119188
[TBL] [Abstract][Full Text] [Related]
14. Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.
Cheung BB; Tan O; Koach J; Liu B; Shum MS; Carter DR; Sutton S; Po'uha ST; Chesler L; Haber M; Norris MD; Kavallaris M; Liu T; O'Neill GM; Marshall GM
Mol Oncol; 2015 Aug; 9(7):1484-500. PubMed ID: 25963741
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency.
Bouchecareilh M; Hutt DM; Szajner P; Flotte TR; Balch WE
J Biol Chem; 2012 Nov; 287(45):38265-78. PubMed ID: 22995909
[TBL] [Abstract][Full Text] [Related]
16. Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells.
Shih YP; Takada Y; Lo SH
Mol Cancer Res; 2012 Jan; 10(1):34-9. PubMed ID: 22064653
[TBL] [Abstract][Full Text] [Related]
17. Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer.
Finnegan E; Ding W; Ude Z; Terer S; McGivern T; Blümel AM; Kirwan G; Shao X; Genua F; Yin X; Kel A; Fattah S; Myer PA; Cryan SA; Prehn JHM; O'Connor DP; Brennan L; Yochum G; Marmion CJ; Das S
Cell Oncol (Dordr); 2024 Apr; 47(2):533-553. PubMed ID: 37934338
[TBL] [Abstract][Full Text] [Related]
18. Molecularly targeted co-delivery of a histone deacetylase inhibitor and paclitaxel by lipid-protein hybrid nanoparticles for synergistic combinational chemotherapy.
Ruttala HB; Ramasamy T; Poudal BK; Choi Y; Choi JY; Kim J; Kwang Ku S; Choi HG; Soon Yong C; Oh Kim J
Oncotarget; 2017 Feb; 8(9):14925-14940. PubMed ID: 28122339
[TBL] [Abstract][Full Text] [Related]
19. Multitargeting HDAC Inhibitors Containing a RAS/RAF Protein Interfering Unit.
Wang Y; Zhang J; Li K; Xia S; Gou S
J Med Chem; 2024 Feb; 67(3):2066-2082. PubMed ID: 38261411
[TBL] [Abstract][Full Text] [Related]
20. REST is a novel prognostic factor and therapeutic target for medulloblastoma.
Taylor P; Fangusaro J; Rajaram V; Goldman S; Helenowski IB; MacDonald T; Hasselblatt M; Riedemann L; Laureano A; Cooper L; Gopalakrishnan V
Mol Cancer Ther; 2012 Aug; 11(8):1713-1723. PubMed ID: 22848092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
